TRIUMEQ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1)

medicine used alone or with other antiretroviral medicines to treat HIV-1
infection
in adults. HIV-1 is the virus that causes AIDS. TRIUMEQ is not for
use by itself in
people who have or have had resistance to abacavir, dolutegravir, or lamivudine.
TRIUMEQ should not be used in children under the age of 18.

TRIUMEQ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1) medicine used alone or with other antiretroviral medicines to treat HIV-1 infection in adults.

Could TRIUMEQ be an HIV-1 treatment for you to move forward with?

TRIUMEQ is a once-a-day pill used to treat HIV-1. In
some people, TRIUMEQ should not be used by itself.


Take TRIUMEQ exactly as your healthcare provider
tells you.

*Real patients with HIV-1 taking TRIUMEQ as of 2014 or later. Individual results may vary. Individuals compensated for their time by ViiV Healthcare.

TRIUMEQ is a prescription HIV-1 (Human Immunodeficiency Virus-type 1)

medicine used alone or with other antiretroviral medicines to treat HIV-1
infection
in adults. HIV-1 is the virus that causes AIDS. TRIUMEQ is not for
use by itself in
people who have or have had resistance to abacavir, dolutegravir, or lamivudine.
TRIUMEQ should not be used in children under the age of 18.

TRIUMEQ is a once-a-day pill used to treat HIV-1. In
some people, TRIUMEQ should not be used by itself.


Take TRIUMEQ exactly as your healthcare provider
tells you.

4 things to consider
about TRIUMEQ

TRIUMEQ pill bottle
one pill

TRIUMEQ is one pill, taken once a day.

TRIUMEQ is not for use by itself in some people. Take TRIUMEQ exactly as your healthcare provider tells you.

night or day

It can be taken day or night, around the same time each day.

with or without food

You can take TRIUMEQ with or without food.

not a booster

TRIUMEQ works without the need for a booster.

How to pronounce TRIUMEQ: TRI-u-meck.

The HLA-B*5701 screening test

Before you take TRIUMEQ, your doctor will give you a genetic screening test if you have not already had one. If you test positive for the HLA-B*5701 gene variation, you can't take TRIUMEQ.

If your
HLA-B*5701 test
is Positive

+
  • You have the HLA-B*5701 gene variation.
  • This means you should not take medicines containing abacavir, including TRIUMEQ.
  • You have a much higher risk for a serious allergic reaction (hypersensitivity reaction) that can cause death if you take medicines containing abacavir, including TRIUMEQ.

If your
HLA-B*5701 test
is Negative

  • You do not have the HLA-B*5701 gene variation.
  • You may still have a hypersensitivity reaction to TRIUMEQ, though the risk is much lower.
  • Ask your doctor if a medicine containing abacavir, like TRIUMEQ, may be right for you.

TRIUMEQ by the numbers

Clinical information about TRIUMEQ: SINGLE Study

In SINGLE, a medical study with 833 adult patients who have HIV-1 infection and had never taken HIV-1 treatment before, more patients got to undetectable (less than 50 copies of HIV-1 RNA in a mL of blood) with TRIUMEQ than with Atripla®. The difference in results was mostly due to more patients stopping their medicine due to side effects on Atripla than TRIUMEQ.

Your results may vary.

SINGLE Study Results
at 144 weeks
(About 3 years):

Triumeq
71%

of patients who took TRIUMEQ reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

378 cells/mm3

was the average increase in CD4+ T-cell count* in patients who took TRIUMEQ.

4%

of patients stopped taking TRIUMEQ due to side effects.

Atripla
63%

of patients who took Atripla reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

332 cells/mm3

was the average increase in CD4+ T-cell count* in patients who took Atripla.

14%

of patients stopped taking Atripla due to side effects.

  • *CD4 cells (also called T-cells) are white blood cells that help fight infections. CD4 cell count is the number of CD4 T-cells per mL of blood.

Most Common Medium to
Severe Side Effects
NOTED IN SINGLE STUDY Occurring at a Frequency OF AT LEAST 2% AT 144 WEEKS
(About 3 years):

Triumeq
3%

of patients experienced trouble sleeping.

2%

of patients experienced headaches.

2%

of patients experienced tiredness.

Atripla
3%

of patients experienced trouble sleeping.

2%

of patients experienced headaches.

2%

of patients experienced tiredness.

Clinical information about TRIUMEQ in women: ARIA Study

ARIA was a 48-week medical study with 495 adult women who had never taken HIV-1 medicines before. The women were split into two groups: one group was given TRIUMEQ and the other group was given Reyataz®/Norvir®/Truvada®.

ARIA was an open-label study, so both the patients and the healthcare providers knew which medicine the patients were taking.

Your results may vary.

ARIA STUDY Results
at 48 weeks (About a year):

Triumeq
82%

of women who took TRIUMEQ reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

234 cells/mm3

was the average increase in CD4+ T-cell count* in women who took TRIUMEQ.

4%

of women taking TRIUMEQ stopped taking it because of side effects.

Reyataz + Norvir + Truvada
71%

of women who took Reyataz + Norvir + Truvada reached undetectable (less than 50 copies of HIV-1 in a mL of blood).

200 cells/mm3

was the average increase in CD4+ T-cell count* in women who took Reyataz + Norvir + Truvada.

7%

of women taking Reyataz + Norvir + Truvada stopped taking it because of side effects.

  • *CD4 cells (also called T-cells) are white blood cells that help fight infections. CD4 cell count is the number of CD4 T-cells per mL of blood.

Most Common Medium to
Severe Side Effects from the ARIA study at a frequency of at least 2% at 48 WEEKS
(About a year):

Triumeq
1%

of patients experienced nausea.

1%

of patients experienced headaches.

1%

of patients experienced rash.*

Reyataz + Norvir + Truvada
4%

of patients experienced nausea.

2%

of patients experienced headaches.

4%

of patients experienced rash.*

  • *Includes rash, rash with bumps, and itchy rash.
  • You are encouraged to report negative side effects of prescription drugs to the FDA.
    Visit www.fda.gov/medwatch, or call 800-FDA-1088.